News | Remote Monitoring | February 17, 2016

Remote Telemonitoring Does Not Reduce Heart Failure Readmissions

While readmissions, mortality do not decrease, researchers see improvements in 180-day quality of life compared to standard care

February 17, 2016 — Increasingly patients and providers are interested in using remote monitoring devices to help with their healthcare. Researchers at the University of California Los Angeles (UCLA) sought to determine if these devices could be useful in preventing 180-day all-cause hospital readmissions for heart failure patients.

They enrolled 1,437 patients from UCLA, UC Davis, UC Irvine, UC San Diego, UC San Francisco and Cedars-Sinai Medical Center in Los Angeles who were randomized into two groups. One group received pre-discharge self-management health coaching along with a Bluetooth-enabled scale, Bluetooth blood pressure/text message device and a transmission pod, and were asked to do daily measurements and answer symptom questions. These measures were checked daily by a centralized nurse call center and if measurements were too high or too low, patients were called to determine what the problem was and if necessary were referred to their healthcare providers or an emergency department. Patients also received scheduled reinforcement of health coaching on a weekly basis for the first month and then monthly through six months. The control group received standard care. The enrollment procedures had very few exclusion criteria in order to mirror potential actual use by health systems, so that patients with a wide range of socioeconomic backgrounds and health comorbidities were enrolled in the study.

The researchers found that combined health coaching and remote monitoring did not reduce all-cause 180-day hospital readmissions among heart failure patients, and did not have significant effects on 30-day hospital readmissions, 30-day mortality or 180-day mortality. These findings were previously reported at the American Heart Association (AHA) scientific meeting on Nov. 8, 2015.

This study additionally reported on quality of life findings not presented at the AHA meeting. The researchers found that intervention patients reported significantly improved quality of life at 180 days when compared to usual care patients based on the Minnesota Living with Heart Failure questionnaire, a well-validated instrument for measuring quality of life among heart failure patients.

The authors concluded that the use of remote monitoring technology is not yet ready for widespread adoption for the purposes of reducing readmissions. A major issue requiring further research is who can adhere to using these technologies and how to improve adherence. Also, further research is needed to evaluate quality of life benefits.

Michael Ong, M.D., Ph.D., associate professor-in-residence of medicine in the division of general internal medicine and health services research at the David Geffen School of Medicine at UCLA, is the study’s lead investigator.

Results were published in the Feb. 8 issue of JAMA Internal Medicine.

For more information: www.archinte.jamanetwork.com/journal

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Overlay Init